West Haven, Connecticut 06516


The overall purpose of this study is to examine the effect of pregnenolone (PREG) on the acute psychosis-like and cognitive effects of Delta-9-tetrahydrocannabinol (THC). This will be tested by pretreating healthy individuals with PREG and then assessing their responses to THC.


Inclusion Criteria: - Exposed to cannabis at least once in lifetime. Exclusion Criteria: - Cannabis naive - Individuals with a documented reaction/allergy to Pregnenolone



Primary Contact:

Principal Investigator
Deepak C D'Souza, MD
Yale University

Leigh Taylor Flynn, BS
Phone: 203-932-5711 ext. 2557
Email: leigh.flynn@yale.edu

Backup Contact:

Email: christina.luddy@yale.edu
Christina Luddy, BS
Phone: 203-932-5711 ext. 4549

Location Contact:

West Haven, Connecticut 06516
United States

Ashley Sanders, BA
Phone: 203-932-5711
Email: ashley.sanders@yale.edu

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.